Project Grant R43TR004525
Award Date
8/1/23
Completion Date
7/31/24
Dollars Obligated
$650K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
This $295,780 federal Project Grant was awarded by the National Center for Complementary and Integrative Health (NCCIH) under the Research and Training in Complementary and Integrative Health program (CFDA 93.213). The grant will be used by Nemalife Inc., a for-profit biotechnology company, to develop a high-throughput in vivo screening platform for identifying novel probiotic and postbiotic bacterial strains that may have therapeutic potential for treating human health disorders associated with...
This $350,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under the 93.350 CFDA program, supports the development of the Codomax EPI-MAX platform. This integrated omics and computational technology leverages cellular stress responses to enhance the production of difficult-to-express therapeutic proteins, with a focus on improving secretion and preventing aggregation in the Pichia pastoris expression system. The key products or services to be...
The National Institutes of Health (NIH) has awarded a $1,333,682 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to North Carolina State University (NC State) to develop peptide inhibitors that neutralize bacterial toxins and deliver them using engineered probiotic yeast. This 3-year project aims to expand on NC State's previous work identifying a lead peptide inhibitor of Clostridioides difficile toxin, by screening for inhibitors of 5 additional bacterial toxins. The...
This $506,000 Project Grant award from the National Center for Complementary and Integrative Health (NCCIH), under the Research and Training in Complementary and Integrative Health program (CFDA 93.213), aims to develop new preventive and treatment modalities against enteric infections. The primary awardee, Scripps Research Institute, will evaluate the activity of recombinant Enterococcus peptidoglycan hydrolase hydrogel formulations in mouse models of enteric infection (Aim 1) and explore...
This federal Project Grant award from the U.S. Department of Agriculture's National Institute of Food and Agriculture (CFDA 10.212 - Small Business Innovation Research (SBIR) Program / Small Business Technology Transfer (STTR) Program) provides $175,000 to Seia Bio Inc. to develop a proprietary coating technology that protects beneficial probiotic microbes, such as Faecalibacterium, from environmental stressors. This will enable the expanded use of these microbes as alternatives to antibiotics...
This $325,139 federal Project Grant award, funded by the National Center for Advancing Translational Sciences (NCATS), 93.350 program, aims to examine the feasibility of using target-specific polyclonal antibodies to neutralize bioactive molecules in the gut microbiome. The primary goals are to 1) determine the impact of six proteins identified as overabundant in inflammatory gut disorders, and 2) evaluate the ability of immunoglobulin Y (IgY) antibodies to neutralize the physiological impacts...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), awarded under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $672,063 to the University of South Florida (USF) to support the "Development of Probiotic-Based and Clostridioides Difficile-Targeted Therapeutics". The award period runs from May 28, 2024 to March 31, 2026. The primary goal of this project is to develop novel non-antibiotic therapeutics that...
The National Institute of General Medical Sciences (NIGMS) awarded a $382,136 Project Grant (CFDA 93.859 Biomedical Research and Research Training) to the University of Maryland, College Park to develop engineering principles for designing programmable bioengineered multicellular structures (probioms) in prokaryotic cells. The goal is to create a new class of probiotic-based therapeutic materials that can be tailored for various biomedical applications, such as anticavity pastes, vaginal creams,...
This Project Grant award, funded by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to develop a system for targeted delivery of engineered probiotic bacteria that secrete an anti-inflammatory cytokine to treat periodontitis. The total award is $873,546 over a 2-year period from September 2024 to September 2026. The project's goal is to use the commercial probiotic Limosilactobacillus reuteri that has...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $202,274 to Acpharis to develop an algorithm and software for predicting the structure and degradation efficiency of proteolysis targeting chimeras (PROTACs). PROTACs are a valuable technology for modulating target proteins by degradation. The key objectives are: 1) Implement a protocol for accurately predicting PROTAC ternary...